medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-17-84-89medsovet-1588Research ArticleИНФЕКЦИОННЫЕ БОЛЕЗНИINFECTIOUS DISEASESСовременные схемы антиретровирусной терапииModern antiretroviral regimensКравченкоА. В.KravchenkoA. V.

д.м.н.

Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора, МоскваРоссияCentral Research Institute of Epidemiology, MoscowRussian Federation2016301220160178489Copyright © Кравченко А.В., 20162016Кравченко А.В.Kravchenko A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1588

В статье представлены результаты крупных международных исследований (STARTMRK, ACTG A5257, SPRING 2, SINGLE и FLAMINGO), которые убедительно показали эффективность и безопасность препаратов из группы ИИ (ралтегравир и долутегравир) в составе схем АРТ у больных ВИЧ-инфекцией, только начинающих лечение (схемы первой линии). Сравнение в течение 2–5 лет терапии схем, включавших ИИ или EFV, показало сопоставимую или большую вирусологическую и иммунологическую эффективность RAL и DTG при существенно более низкой частоте развития нежелательных явлений при применении этих препаратов. Препараты из группы RAL и DTG являются препаратами выбора и у особых категорий пациентов с ВИЧ-инфекцией (больные туберкулезом или хроническим гепатитом С). В статье представлены результаты двух исследований, проведенных в России, по эффективности и безопасности применения ралтегравира в схемах АРТ у больных ВИЧ-инфекцией и туберкулезом и у пациентов с ВИЧ-инфекцией и хроническим гепатитом С. 

The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and dolutegravir) as part of ART regimens in HIV-infected patients who are just beginning treatment (first line regimens). Comparisons within 2–5 years regimens that included II or EFV, showed comparable or greater virological and immunological efficacy of RAL and DTG at a substantially lower incidence of adverse events with the use of these drugs. Preparations of the RAL group and DTG are the drugs of choice and special categories of patients with HIV infection (patients with tuberculosis or chronic hepatitis C). The article presents the results of two studies carried out in Russia, on the efficacy and safety of raltegravir in ART regimens in patients with HIV infection and tuberculosis, and in patients with HIV infection and chronic hepatitis C. 

ВИЧ-инфекцияАРТингибиторы интегразыралтегравирдолутегравирHIV infectionARTintegrase inhibitorsraltegravirdolutegravirReferencesGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) January 28, 2016 (http://AIDSinfo.nih.gov).Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) January 28, 2016 (http://AIDSinfo.nih.gov).Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 8.0; October, 2015). European AIDS Clinical Society (http://www.europeanaidsclinicalsociety.org).Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 8.0; October, 2015). European AIDS Clinical Society (http://www.europeanaidsclinicalsociety.org).Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г. и соавт. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией 2015. Эпидемиология и инфекционные болезни. Актуальные вопросы, 2015, 6(Приложение 1), 120 с. / Pokrovsky V.V., Yurin O.G., Kravchenko A.V.., Belyaeva V.V., Ermak T.N., Kanestri V.G. et al. Acts of follow-up and treatment of patients with HIV-infection. Epidemiologya I infektsion nye bolezni. Aktual’nye voprosy, 2015, 6(supplement), 120 p.Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г. и соавт. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией 2015. Эпидемиология и инфекционные болезни. Актуальные вопросы, 2015, 6(Приложение 1), 120 с. / Pokrovsky V.V., Yurin O.G., Kravchenko A.V.., Belyaeva V.V., Ermak T.N., Kanestri V.G. et al. Acts of follow-up and treatment of patients with HIV-infection. Epidemiologya I infektsion nye bolezni. Aktual’nye voprosy, 2015, 6(supplement), 120 p.Кравченко А.В. Ралтегравир – первый ингибитор интегразы вируса иммунодефицита в составе схем антиретровирусной терапии. Терапевтический архив, 2010, 82(11): 27-32. / Kravchenko A.V. Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens. Terapevticheskii arkhiv, 2010, 82(11): 27-32.Кравченко А.В. Ралтегравир – первый ингибитор интегразы вируса иммунодефицита в составе схем антиретровирусной терапии. Терапевтический архив, 2010, 82(11): 27-32. / Kravchenko A.V. Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens. Terapevticheskii arkhiv, 2010, 82(11): 27-32.Кравченко А.В., Максимов С.Л. Новый ингибитор интегразы ВИЧ долутегравир в схемах антиретровирусной терапии у пациентов, ранее не получавших лечения. Инфекционные болезни: новости, мнения, обучение, 2015, 4: 96-102. / Kravchenko A.V., Maksimov S.L. New HIV integrase inhibitor dolutegravir – based antiretroviral therapy in previously untreated patients. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2015, 4: 96-102.Кравченко А.В., Максимов С.Л. Новый ингибитор интегразы ВИЧ долутегравир в схемах антиретровирусной терапии у пациентов, ранее не получавших лечения. Инфекционные болезни: новости, мнения, обучение, 2015, 4: 96-102. / Kravchenko A.V., Maksimov S.L. New HIV integrase inhibitor dolutegravir – based antiretroviral therapy in previously untreated patients. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2015, 4: 96-102.Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C et al. ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, con￾trolled equivalence trial. Ann Intern Med, 2014 Oct 7, 161(7): 461-71. doi: 10.7326/M14-1084.Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C et al. ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, con￾trolled equivalence trial. Ann Intern Med, 2014 Oct 7, 161(7): 461-71. doi: 10.7326/M14-1084.Gotuzzo E, Markowitz M, Ratanasuwan W, Smith G, Prada G, Morales-Ramirez JO et al. Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr, 2012, 61(1): 73-77.Gotuzzo E, Markowitz M, Ratanasuwan W, Smith G, Prada G, Morales-Ramirez JO et al. Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr, 2012, 61(1): 73-77.Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-A et al. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. Publish Ahead of Print. DOI: 10.1097/QAI.0000000000000790.Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-A et al. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. Publish Ahead of Print. DOI: 10.1097/QAI.0000000000000790.Molina J-M, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K et al. on behalf of the FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatmentnaive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet, 2015 HIV, 2: e127-36. Published Online March 10, 2015 http://dx.doi. org/10.1016/ S2352-3018(15)00027-2.Molina J-M, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K et al. on behalf of the FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatmentnaive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet, 2015 HIV, 2: e127-36. Published Online March 10, 2015 http://dx.doi. org/10.1016/ S2352-3018(15)00027-2.Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. on behalf of the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis., 2013, 13: 927-35. http://dx. doi.org/10.1016/ S1473-3099(13)70257-3.Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. on behalf of the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis., 2013, 13: 927-35. http://dx. doi.org/10.1016/ S1473-3099(13)70257-3.American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/fullreport-view. (Updated: February 24, 2016. Changes made: March 24, 2016).American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/fullreport-view. (Updated: February 24, 2016. Changes made: March 24, 2016).European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. Available at: http://www.easl. eu/medias/cpg/HEPC-2015/Full-report. pdf. (accessed on August 19, 2015).European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. Available at: http://www.easl. eu/medias/cpg/HEPC-2015/Full-report. pdf. (accessed on August 19, 2015).Grinsztejn B, De Castro N, Arnold V. A randomized multicenter open-label trial to estimate the efficacy and safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the treatment of HIV-TB co-infected patients: results of the ANRS 12 180 Reflate TB trial. Program and abstracts of the XIX International AIDS Conference, July 22-27, 2012, Washington, DC. Abstract THLBB01.Grinsztejn B, De Castro N, Arnold V. A randomized multicenter open-label trial to estimate the efficacy and safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the treatment of HIV-TB co-infected patients: results of the ANRS 12 180 Reflate TB trial. Program and abstracts of the XIX International AIDS Conference, July 22-27, 2012, Washington, DC. Abstract THLBB01.Кравченко А.В., Зимина В.Н., Попова А.А., Деулина М.О., Канестри В.Г., Иванова Э.С., Яковлев А.А., Покровский В.В. Эффективность и безопасность схемы терапии, включающей ралтегравир и комбинированный препарат с фиксированными дозами ламивудина и абакавира, у пациентов с туберкулезом и ВИЧ-инфекцией, получавших рифабутин. Терапевтический архив, 2014, 86(11): 34-41. / Kravchenko A.V., Zimina V.N., Popova A.A., Deulina M.O., Kanestri V.G., Ivanova E.S., Yakovlev A.A., Pokrovsky V.V. The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutintreated patients with tuberculosis and HIV infection. Terapevticheskii arkhiv, 2014, 86 (11): 34-41.Кравченко А.В., Зимина В.Н., Попова А.А., Деулина М.О., Канестри В.Г., Иванова Э.С., Яковлев А.А., Покровский В.В. Эффективность и безопасность схемы терапии, включающей ралтегравир и комбинированный препарат с фиксированными дозами ламивудина и абакавира, у пациентов с туберкулезом и ВИЧ-инфекцией, получавших рифабутин. Терапевтический архив, 2014, 86(11): 34-41. / Kravchenko A.V., Zimina V.N., Popova A.A., Deulina M.O., Kanestri V.G., Ivanova E.S., Yakovlev A.A., Pokrovsky V.V. The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutintreated patients with tuberculosis and HIV infection. Terapevticheskii arkhiv, 2014, 86 (11): 34-41.Кравченко А.В., Аксенова В.Я., Гуркина Л.А., Жуков В.В., Иванова Э.С., Козырев О.А. и соавт. Ингибитор интегразы ВИЧ ралтегравир в составе схем антиретровирусной терапии у больных ВИЧ-инфекцией и гепатитом С. Инфекционные болезни, 2015, 13(3): 5-11. / Kravchenko A.V., Aksenova V.Ya., Gurkina L.A., Zhukov V.V., Ivanova E.S., Kozyrev O.A., Nagimova F.I., Strebkova E.A., Chernova O.E., Pokrovsky V.V. The HIV integrase inhibitor raltegravir as part of antiretroviral therapy schemes in patients with HIV infection and hepatitis C. Infektsionnye bolezni, 2015, 13(3): 5-11.Кравченко А.В., Аксенова В.Я., Гуркина Л.А., Жуков В.В., Иванова Э.С., Козырев О.А. и соавт. Ингибитор интегразы ВИЧ ралтегравир в составе схем антиретровирусной терапии у больных ВИЧ-инфекцией и гепатитом С. Инфекционные болезни, 2015, 13(3): 5-11. / Kravchenko A.V., Aksenova V.Ya., Gurkina L.A., Zhukov V.V., Ivanova E.S., Kozyrev O.A., Nagimova F.I., Strebkova E.A., Chernova O.E., Pokrovsky V.V. The HIV integrase inhibitor raltegravir as part of antiretroviral therapy schemes in patients with HIV infection and hepatitis C. Infektsionnye bolezni, 2015, 13(3): 5-11.

The authors declare that there are no conflicts of interest present.